meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1)
2
mCRC - 2nd line (L2)
3
endometrial cancer
10
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
avelumab based treatment
avelumab plus SoC
dostarlimab based treatment
dostarlimab plus soC
durvalumab based treatment
durvalumab plus olaparib plus SoC
durvalumab plus SoC
pembrolizumab based treatment
pembrolizumab plus lenvatinib
pembrolizumab plus SoC
poly ADP-ribose polymerase (PARP) inhibitor
niraparib
VEGF(R) inhibitor
lenvatinib
lenvatinib in association
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
All patients
dMMR
PD-L1 < 1%
PDL1 (CPS < 1)
PDL1 (CPS >1)
pMMR
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
PFS (extension)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE (grade 3-5)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
SAE (any grade)
deaths (OS)
endometrial cancer
endometrial cancer
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC
1
0.82
[0.63; 1.07], 1 RCT, I2=0%
inconclusive result
dostarlimab plus soC vs. placebo plus SoC
2
0.69
[0.54; 0.89], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
durvalumab plus olaparib plus SoC vs. placebo plus SoC
1
0.59
[0.42; 0.83], 1 RCT, I2=0%
unassessable degree of certainty
durvalumab plus SoC vs. placebo plus SoC
1
0.77
[0.56; 1.06], 1 RCT, I2=0%
inconclusive result
pembrolizumab plus SoC vs. placebo plus SoC
2
-
versus Standard of Care (SoC)
avelumab plus SoC vs. Standard of Care (SoC)
1
1.13
[0.62; 2.06], 1 RCT, I2=0%
inconclusive result
pembrolizumab plus lenvatinib vs. Standard of Care (SoC)
2
0.78
[0.55; 1.10], 2 RCTs, I2=87%
inconclusive result
endometrial cancer - (neo)adjuvant (NA)
endometrial cancer - (neo)adjuvant (NA)
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open